Recombinant follitropin alfa/lutropin alfa in fertility treatment

Biologics: Targets and Therapy

Volumn 4, Issue , 2010, Pages 5-17

  Gibreel, Ahmed ^a   Bhattacharya, Siladitya ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN MATERNITY HOSPITAL   (United Kingdom)

Author keywords

Follicle stimulating hormone; Follitropin alpha; In vitro fertilization; Infertility; Luteinizing hormone; Lutropin alpha; Urinary gonadotrophins

Indexed keywords

CHORIONIC GONADOTROPIN; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PLACEBO; RECOMBINANT FOLLITROPIN;

ABDOMINAL PAIN; AZOOSPERMIA; BIOLOGICAL ACTIVITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; IDIOPATHIC DISEASE; INFERTILITY THERAPY; INJECTION SITE PAIN; INJECTION SITE REACTION; LOCAL SKIN REACTION; LOW DRUG DOSE; MALE INFERTILITY; MASTALGIA; MULTIPLE CYCLE TREATMENT; MULTIPLE PREGNANCY; NAUSEA; NONHUMAN; OLIGOSPERMIA; OVARY CYST; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATIENT SATISFACTION; PRURITUS; REVIEW; SINGLE DRUG DOSE; SKIN IRRITATION; SKIN PAIN; SUBFERTILITY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77951165918     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Smith MG. On the interruption of pregnancy in the rat by the injection of ovarian follicular extract. Bull Johns Hopkins Hosp. 1926;39(4):203-214.
2. Fevold SL, Hisaw FL, Leonard SL. The gonad-stimulating and the luteinizing hormones of the anterior lobe of the hypophysis. Am J Physiol. 1931;97:291-301.
3. Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update. 2004;10(6):453-467.
4. Gemzell CA, Diczfalusy E, Tillinger G. Clinical effect of human pituitary follicle-stimulating hormone (FSH). J Clin Endocrinol Metab. 1958;18(12):1333-1348.
5. Lunenfel D B. Development of gonadotrophins for clinical use. Reprod Biomed Online. 2002;4 Suppl:111-117.
6. Dumble LJ, Klein RD. Creutzfeldt-Jakob legacy for Australian women treated with human pituitary gonadotropins. Lancet. 1992;340(8823):847-848.
7. Cochius JI, Burns RJ, Blumbergs PC, Mack K, Alderman CP. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. Aust NZ J Med. 1990;20(4):592-593.
8. Strowitzki T. Biotechnological drugs for reproductive disorders: a review of developments. BioDrugs. 1997;8(5):360-370.
9. Gordon K. New developments in gonadotrophin pharmacology. Reprod Biomed Online. 2002;5(3):259-264.
10. Giudice LC. Insulin-like growth factor family in Graafian follicle development and function. J Soc Gynecol Investig. 2001;8(1 Suppl Proceedings):S26-S29.
11. Wolfenson C, Groisman J, Couto AS, et al. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recom-binant preparations. Reprod Biomed Online. 2005;10(4):442-454.
12. Howles CM. Genetic engineering of human FSH (Gonal-F). Hum Reprod Update. 1996;2(2):172-191.
13. Olijve W, de Boer W, Mulders JW, van Wezenbeek PM. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod. 1996;2(5):371-382.
14. Alper M, Meyer R, Dekkers C, Ezcurra D, Schertz J, Kelly E. Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats. Reprod Biol Endocrinol. 2008;6:31-36.
15. Saz-Parkinson Z, López-Cuadrado T, Bouza C, Amate JM. Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies. BioDrugs. 2009;23(1):37-42.
16. Agostinetto R. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment. Reprod Biol Endocrinol. 2009;7:48-52.
17. http://www.emea.europa.eu/humandocs/PDFs/EPAR/pergoveris/H-714-en1.pdf
18. Pierce JG, Faith MR, Giudice LC, Reeve JR. Structure and structure-function relationships in glycoprotein hormones. Ciba Found Symp. 1976;41:225-250.
19. Gordon K, Prins M, Schuller K, Lewin J. One million and counting. Reprod Biomed Online. 2006;13(3):313-314.
20. Goa KL, Wagstaff AJ. Follitropin alpha in infertility: a review. BioDrugs. 1998;9(3):235-260.
21. Wide L, Bakos O. More basic forms of both human follicle-stimulating hormone and luteinizing hormone in serum at midcycle compared with the follicular or luteal phase. J Clin Endocrinol Metab. 1993;76(4): 885-889.
22. Papandreou MJ, Asteria C, Pettersson K, Ronin C, Beck-Peccoz P. Con-canavalin A affinity chromatography of human serum gonadotropins: evidence for changes of carbohydrate structure in different clinical conditions. J Clin Endocrinol Metab. 1993;76(4):1008-1013.
23. Green ED, Baenziger JU. Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin. II. Distributions of sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones. J Biol Chem. 1988;263(1):36-44.
24. Dahl KD, Stone MP. FSH isoforms, radioimmunoassays, bioassays, and their significance. J Androl. 1992;13(1):11-22.
25. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimula-tion with highly purified hMG or recombinant FSH in patients under-going IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21(12):3217-3227.
26. Lambert A, Rodgers M, Mitchell R, et al. In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. Hum Reprod. 1995;10(7):1928-1935.
27. Mitchell R, Bauerfeld C, Schaefer F, Scharer K, Robertson WR. Less acidic forms of luteinizing hormone are associated with lower testos-terone secretion in men on haemodialysis treatment. Clin Endocrinol (Oxf). 1994;41(1):65-73.
28. Chappel SC. Heterogeneity of follicle stimulating hormone: control and physiological function. Hum Reprod Update. 1995;5:479-487.
29. Zambrano E, Olivares A, Mendez JP, et al. Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle. J Clin Endocrinol Metab. 1995;80(5):1647-1656.
30. Anobile CJ, Talbot JA, McCann SJ, Padmanabhan V, Robertson WR. Glycoform composition of serum gonadotrophins through the normal menstrual cycle and in the post-menopausal state. Mol Hum Reprod. 1998;4(7):631-639.
31. Bishop LA, Nguyen TV, Schofield PR. Both of the beta-subunit carbohydrate residues of follicle-stimulating hormone determine the metabolic clearance rate and in vivo potency. Endocrinology. 1995;136(6):2635-2640.
32. Dhillon S, Keating GM. Lutropin alfa. Drugs. 2008;68(11):1529-1540.
33. Loumaye E, Engrand P, Howles CM, O'Dea L. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril. 1997;67(5):889-899.
34. Weston AM, Zelinski-Wooten MB, Hutchison JS, Stouffer RL, Wolf DP. Developmental potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone. Hum Reprod. 1996;11(3):608-613.
35. Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod. 1995;10(7):1658-1666.
36. Burgues S. Spanish Collaborative Group on Female Hypogonadotrophic Hypogonadism. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum Reprod. 2001;16(12):2525-2532.
37. Recombinant LH Study Group. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod. 2005;20(3):629-635.
38. Loumaye E. Ovarian stimulation: is exogenous LH necessary in all patients? Gynecol Obstet Fertil. 2002;30(11):890-895.
39. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH ceiling? Hum Reprod. 2003;18(12):2719-2720.
40. Lockwood GM, Muttukrishna S, Groome NP, Knight PG, Ledger WL. Circulating inhibins and activin A during GnRH-analogue down-regulation and ovarian hyperstimulation with recombinant FSH for in-vitro fertilization-embryo transfer. Clin Endocrinol (Oxf). 1996;45(6):741-748.
41. Fisch B, Avrech OM, Pinkas H, et al. Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study. J Assist Reprod Genet. 1995;12(1):26-31.
42. le Cotonnec JY, Loumaye E, Porchet HC, Beltrami V, Munafo A. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril. 1998;69(2):201-209.
43. Karlsson MO, Wade JR, Loumaye E, Munafo A. The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women. Br J Clin Pharmacol. 1998;45(1):13-20.
44. le Cotonnec JY, Porchet HC, Beltrami V, Munafo A. Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. Fertil Steril. 1998;69(2):189-194.
45. le Cotonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril. 1994;61(4):669-678.
46. Baer G, Loumaye E. Comparison of recombinant human luteinising hormone (r-hLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology. Curr Med Res Opin. 2003;19(2):83-88.
47. Siebold B. Physicochemical characterization of recombinant human follicle stimulating hormone. Hum Reprod. 1996;11 Suppl:1109-1115; discussion 117-119.
48. Driebergen R, Baer G. Quantification of follicle stimulating hormone (follitropin alfa): is in vivo bioassay still relevant in the recombinant age? Curr Med Res Opin. 2003;19(1):41-46.
49. Lispi M, Bassett R, Crisci C, et al. Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin alpha). Reprod Biomed Online. 2006;13(2):179-193.
50. Lass A, McVeigh E; UK Gonal-f FbM PMS Group. Routine use of r-hFSH follitropin alfa filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK. Reprod Biomed Online. 2004;9(6):604-610.
51. Wikland M, Hugues JN, Howles C. Improving the consistency of ovarian stimulation: follitropin alfa filled-by-mass. Reprod Biomed Online. 2006;12(6):663-668.
52. Keck C, Bassett R, Ludwig M. Factors influencing response to ovarian stimulation. Reprod Biomed Online. 2005;11(5):562-569.
53. http//www.fda.gov/cder/foi/label/2004/21322/lbl.pdf
54. Dickey RP. Strategies to reduce multiple pregnancies due to ovulation stimulation. Fertil Steril. 2009;91(1):1-17.
55. Van Loon K. Safety of high doses of recombinant human growth hormone. Horm Res. 1998;49(# Suppl 2):78-81.
56. Hugues JN. Recombinant human follicle-stimulating hormone: a scientific step to clinical improvement. Reprod Biomed Online. 2001;2(1):54-64.
57. Recombinant Human FSH Study Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil Steril. 1995;63(1):77-86.
58. Bergh C, Howles CM, Borg K, et al. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod. 1997;12(10):2133-2139.
59. Balen A, Platteau P, Andersen AN, Devroey P, Helmgaard L, Arce JC; for the Bravelle Ovulation Induction (BOI) Study Group. Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod. 2007;22(7): 1816-1823.
60. Loret de Mola JR, Kiwi R, Austin C, Goldfarb JM. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril. 2000;73(6):1253-1256.
61. Bar J, Orvieto R, Lahav J, Hod M, Kaplan B, Fisch B. Effect of urinary versus recombinant follicle-stimulating hormone on platelet function and other hemostatic variables in controlled ovarian hyperstimulation. Fertil Steril. 2004;82(6):1564-1569.
62. Hedon B, Hugues JN, Emperaire JC, et al. A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum Reprod. 1998;13(10):2688-2692.
63. Harrison S, Wolf T, Abuzeid MI. Administration of recombinant follicle stimulating hormone in a woman with allergic reaction to menotropin: a case report. Gynecol Endocrinol. 2000;14(3):149-152.
64. Phipps WR, Holden D, Sheehan RK. Use of recombinant human follicle-stimulating hormone for in vitro fertilization-embryo transfer after severe systemic immunoglobulin E-mediated reaction to urofol-litropin. Fertil Steril. 1996;66(1):148-150.
65. Brinsden P, Akagbosu F, Gibbons LM, et al. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2000;73(1):114-116.
66. Orvieto R, Nahum R, Rabinson J, Ashkenazi J, Anteby EY, Meltcer S. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference? Fertil Steril. 2009;91(4 Suppl):1522-1525.
67. Fried G, Harlin J, Wramsby H. Recombinant FSH - clinical experience with two different preparations. Fertil Steril. 1998;70 Suppl 1:S112.
68. Egbase PE. Severe OHSS: how many cases are preventable? Hum Reprod. 2000;15(1):8-10.
69. Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod. 2002;17(12):3027-3032.
70. Buyalos RP, Lee CT. Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. Fertil Steril. 1996;65(1):1-10.
71. MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod. 1993;8(2):233-237.
72. Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril. 1990;53(3):502-509.
73. Fauser BC,Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18(1):71-106.
74. Balasch J, Fabregues F, Penarrubia J, et al. Outcome from consecutive assisted reproduction cycles in patients treated with recombinant follitropin alfa filled-by-bioassay and those treated with recombinant follitropin alfa filled-by-mass. Reprod Biomed Online. 2004;8(4): 408-413.
75. Balasch J, Penarrubia J, Fabregues F, et al. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction. Reprod Biomed Online. 2003;7(1):35-42.
76. European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78(3): 520-528.
77. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008;16(1):81-88.
78. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23(2):310-315.
79. Mochtar MH, Van der V, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2007;2: CD005070.
80. Timeva T, Milachich T, Antonova I, Arabaji T, Shterev A, Omar HA. Correlation between number of retrieved oocytes and pregnancy rate after in vitro fertilization/intracytoplasmic sperm infection. Scientific WorldJournal. 2006;6686-690.
81. van Rumste MM, Custers IM, van der Veen F, van Wely M, Evers JL, Mol BW. The influence of the number of follicles on pregnancy rates in intrauterine insemination with ovarian stimulation: a meta-analysis. Hum Reprod Update. 2008;14(6):563-570.
82. Sedbon E, Wainer R, Perves C. Quality of life of patients undergoing ovarian stimulation with injectable drugs in relation to medical practice in France. Reprod Biomed Online. 2006;12(3):298-303.
83. Palermo R. Differential actions of FSH and LH during folliculogenesis. Reprod Biomed Online. 2007;15(3):326-337.
84. O'Dea L, O'Brien F, Currie K, Hemsey G. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 2008;24(10):2785-2793.
85. Kliesch S, Behre HM, Nieschlag E. Recombinant human follicle-stimulating hormone and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male. Fertil Steril. 1995;63(6):1326-1328.
86. Arslan AA, Gu Y, Zeleniuch-Jacquotte A, et al. Reproducibility of serum pituitary hormones in women. Cancer Epidemiol Biomarkers Prev. 2008;17(8):1880-1883.
87. Dhont M, Onghena A, Coetsier T, De Sutter P. Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction. Hum Reprod. 1995;10(4):791-796.
88. Steures P, van der Steeg JW, Hompes PG, et al. Intra-uterine insemination with controlled ovarian hyperstimulation compared to an expectant management in couples with unexplained subfertility and an intermediate prognosis: a randomised study. Ned Tijdschr Geneeskd. 2008;152(27):1525-1531.
89. Bensdorp AJ, Cohlen BJ, Heineman MJ, Vandekerckhove P. Intrauterine insemination for male subfertility. Cochrane Database Syst Rev. 2007;4(4):CD000360.
90. Barlow DH. GnRH agonists and in vitro fertilization. J Reprod Med. 1998;43(3 Suppl):245-251.
91. Sbracia M, Colabianchi J, Giallonardo A, et al. Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertil Steril. 2009;91(5):1842-1847.
92. Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol. 2004;115 Suppl 1:S44-S56.
93. Kingsland C, Tan SL, Bickerton N, Mason B, Campbell S. The routine use of gonadotropin-releasing hormone agonists for all patients undergoing in vitro fertilization. Is there any medical advantage? A prospective randomized study. Fertil Steril. 1992;57(4):804-809.
94. Broekmans FJ, Bernardus RE, Berkhout G, Schoemaker J. Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. Gynecol Endocrinol. 1992;6(3):153-161.
95. Abdalla HI, Ahuja KK, Leonard T, Morris NN, Honour JW, Jacobs HS. Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program. Fertil Steril. 1990;53(3):473-478.
96. De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, Molis M. Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod. 2000;15(1):17-20.
97. Mohamed MA, Sbracia M, Pacchiarotti A, et al. Urinary follicle-stimulating hormone (FSH) is more effective than recombinant FSH in older women in a controlled randomized study. Fertil Steril. 2006;85(5):1398-1403.
98. Hompes PG, Broekmans FJ, Hoozemans DA, Schats R, FIRM group. Effectiveness of highly purified human menopausal gonadotropin vs recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril. 2008;89(6):1685-1693.
99. Bosch E, Vidal C, Labarta E, Simon C, Remohi J, Pellicer A. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists - a randomized study. Hum Reprod. 2008;23(10):2346-2351.
100. Shoham Z, Insler V. Recombinant technique and gonadotropins production: new era in reproductive medicine. Fertil Steril. 1996;66(2):187-201.
101. Tulppala M, Aho M, Tuuri T, et al. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study. Hum Reprod. 1999;14(11):2709-2715.
102. Harlin J, Csemiczky G, Wramsby H, Fried G. Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta. Hum Reprod. 2000;15(2):239-244.
103. Platteau P, Andersen AN, Balen A, et al; Menopur Ovulation Induction (MOI) Study Group. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod. 2006;21(7): 1798-1804.
104. Kolibianakis E, Zikopoulos K, Albano C, et al. Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. Reprod Biomed Online. 2003;7(3):313-318.
105. Watson H, Kiddy DS, Hamilton-Fairley D, et al. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod. 1993;8(6):829-833.
106. Oliveira JB, Mauri AL, Petersen CG, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRH-agonist protocol: a meta-analysis. J Assist Reprod Genet. 2007;24(2-3): 67-75.
107. Barrenetxea G, Agirregoikoa JA, Jimenez MR, de Larruzea AL, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril. 2008;89(3):546-553.
108. Kolibianakis EM, Kalogeropoulou L, Griesinger G, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update. 2007;13(5):445-452.
109. Durnerin CI, Erb K, Fleming R, et al; Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod. 2008;23(2):421-426.
110. Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies. Curr Med Res Opin. 2008;24(4):1199-1208.
111. Lachelin GC, Yen SS. Hypothalamic chronic anovulation. Am J Obstet Gynecol. 1978;130(7):825-831.
112. Homburg R. Ovulation induction. Expert Opin Pharmacother. 2003;4(11):1995-2004.
113. Filicori M, Flamigni C, Cognigni G, Dellai P, Michelacci L, Arnone R. Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction. Fertil Steril. 1994;62(2):279-285.
114. The ESHRE Capri Workshop Group. Anovulatory infertility. Hum Reprod. 1995;10(6):1549-1553.
115. Shoham Z, Smith H, Yeko T, O'Brien F, Hemsey G, O'Dea L. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clin Endocrinol (Oxf). 2008;69(3):471-478.
116. Kaufmann R, Dunn R, Vaughn T, et al. Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women. Clin Endocrinol (Oxf). 2007;67(4):563-569.
117. Kousta E, White DM, Piazzi A, Loumaye E, Franks S. Successful induction ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome. Hum Reprod. 1996;11(1):70-71.
118. Campo S, Campo V, Lanzone A. Twin pregnancy using recombinant gonadotropins in a woman with hypogonadotropic hypogonadism. Gynecol Endocrinol. 2002;16(1):27-32.
119. Broekmans FJ, Fauser BC. Diagnostic criteria for polycystic ovarian syndrome. Endocrine. 2006;30(1):3-11.
120. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long- term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
121. Hendriks ML, Brouwer J, Hompes PG, Homburg R, Lambalk CB. LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO II oligo/amenorrhoea. Reprod Biomed Online. 2008; 16(6):765-771.
122. Donderwinkel PF, Schoot DC, Coelingh Bennink HJ, Fauser BC. Pregnancy after induction of ovulation with recombinant human FSH in polycystic ovary syndrome. Lancet. 1992;340(8825):983.
123. Platteau P, Andersen AN, Balen A, et al. Ovulation Induction (MOI) Study Group. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod. 2006;21(7):1798-1804.
124. Revelli A, Poso F, Gennarelli G, Moffa F, Grassi G, Massobrio M. Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis. Reprod Biol Endocrinol. 2006;4:38.
125. Yarali H, Bukulmez O, Gurgan T. Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonadotropic,chronic anovulation: a prospective randomized study. Fertil Steril. 1999;72(2):276-281.
126. Yarali H, Zeyneloglu HB. Gonadotrophin treatment in patients with polycystic ovary syndrome. Reprod Biomed Online. 2004;8(5):528-537.
127. Fulghesu AM, Apa R, Belosi C, et al. Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment. Horm Res. 2001;55(5):224-228.
128. Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2001;2(2):CD002121.
129. Lopez E, Gunby J, Daya S, Parrilla JJ, Abad L, Balasch J. Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reprod Biomed Online. 2004;9(4):382-390.
130. Szilagyi A, Bartfai G, Manfai A, Koloszar S, Pal A, Szabo I. Low-dose ovulation induction with urinary gonadotropins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2004;18(1):17-22.
131. Cristello F, Cela V, Artini PG, Genazzani AR. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol. 2005;21(6):340-352.
132. Leader A; Monofollicular Ovulation Induction Study Group. Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low-dose step-up protocol with weekly increments of 25 international units of follicle-stimulating hormone. Fertil Steril. 2006;85(6):1766-1773.
133. Attia AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev. 2007;(4)(4):CD005071.
134. McLachlan RI. The endocrine control of spermatogenesis. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14(3):345-362.
135. Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, et al. Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study. J Urol. 2005;173:2072-2075.
136. Kamischke A, Behre HM, Bergmann M, Simoni M, Schafer T, Nieschlag E. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod. 1998;13(3):596-603.
137. Foresta C, Selice R, Ferlin A, Garolla A. Recombinant FSH in the treatment of oligozoospermia. Expert Opin Biol Ther. 2009;9(5):659-666.
138. Bakircioglu ME, Erden HF, Ciray HN, Bayazit N, Bahceci M. Gonadotrophin therapy in combination with ICSI in men with hypogonadotrophic hypogonadism. Reprod Biomed Online. 2007;15(2):156-160.
139. Lee KH, Diekman MA, Moss GE, Allrich RD. Pituitary gonadotropins, hypothalamic gonadotropin-releasing hormone, and testicular traits of boars exposed to natural or supplemental lighting during pubertal development. Biol Reprod. 1987;36(5):1164-1169.
140. Cailleux-Bounacer A, Reznik Y, Cauliez B, Menard JF, Duparc C, Kuhn JM. Evaluation of endocrine testing of Leydig cell function using extractive and recombinant human chorionic gonadotropin and different doses of recombinant human LH in normal men. Eur J Endocrinol. 2008;159(2):171-178.
141. Bouloux P, Warne DW, Loumaye E. Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotrophic hypogonadism. Fertil Steril. 2002;77:270-273.
142. Liu PY, Turner L, Rushford D, McDonald J, Baker HW, Conway AJ, et al. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Hum Reprod. 1999;14:1540-1545.
143. Matsumoto AM, Snyder P, Bhasin S, Martin K, Weber T, Winters S, et al. Stimulation of spermatogenesis with recombinant human follicle- stimulating hormone (follitropin alfa; GONAL-f) long-term treatment in azoospermic men with hypogonadotropic hypogonadism (HH). Fertil Steril. 2008. [Epub ahead of print]
144. Okada H, On behalf of the Japanese MHH study group. Recombinant human follicle-stimulating hormone (r-hFSH, follitropin alfa) is efficacious for induction of spermatogenesis and pregnancy in Japanese men with hypogonadotropic hypogonadism. Fertil Steril. 2005; 84(Suppl 1):S222.
145. Warne D, Okada H, Yano Y, Koide N, Howles C. A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril. In press 2009.
146. Liu PY, Gebski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ. Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. Hum Reprod. 2002;17:625-633.
147. Pang S, Kaplan B, Karande V, et al; Follistim Pen Trade Mark COH Study Group. Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation. Reprod Biomed Online. 2003;7(3):319-326.
148. Pang SC. A pen injection device for self-administration of recombinant follicle-stimulating hormone for fertility treatments. Expert Rev Med Devices. 2005;2(1):27-32.
149. Aghssa MM, Azargoon A, Ramezanzadeh F, Bagheri M. A comparison of the efficacy, tolerability, and convenience of two formulations of follitropin-alpha in Iranian woman undergoing intracytoplasmic sperm injection cycles. Fertil Steril. 2008;90(4):1043-1048.
150. Porter R, Kissel C, Saunders H, Keck C. Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens. Curr Med Res Opin. 2008;24(3):727-735.
151. Daya S, Ledger W, Auray JP, et al. Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK. Hum Reprod. 2001;16(12):2563-2569.
152. Hatoum HT, Keye WR Jr, Marrs RP, Walton SM, Marshall DC. A Markov model of the cost-effectiveness of human-derived follicle- stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data. Fertil Steril. 2005;83(3):804-807.
153. Sykes D, Out HJ, Palmer SJ, van Loon J. The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments. Hum Reprod. 2001;16(12):2557-2562.
154. Foresta C, Selice R, Ferlin A, Garolla A. Recombinant FSH in the treatment of oligozoospermia. Expert Opin Biol Ther. 2009;9(5):659-666.
155. Lloyd A, Kennedy R, Hutchinson J, Sawyer W. Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction. Fertil Steril. 2003;80(5):1108-1113.
156. Wechowski J, Connolly M, McEwan P, Kennedy R. An economic evaluation of highly purified HMG and recombinant FSH based on a large randomized trial. Reprod Biomed Online. 2007;15(5):500-506.
157. Al-Inany H, Aboulghar MA, Mansour RT, Proctor M. Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception. Hum Reprod. 2005;20(8):2061-2073.
158. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. HMG versus rFSH for ovulation induction in developing countries: a cost-effectiveness analysis based on the results of a recent meta-analysis. Reprod Biomed Online. 2006;12(2):163-169.
159. Gerli S, Casini ML, Unfer V, Costabile L, Bini V, Di Renzo GC. Recombinant versus urinary follicle-stimulating hormone in intra- uterine insemination cycles: a prospective, randomized analysis of cost effectiveness. Fertil Steril. 2004;82(3):573-578.
160. Gerli S, Bini V, Di Renzo GC. Cost-effectiveness of recombinant follicle-stimulating hormone (FSH) versus human FSH in intrauterine insemination cycles: a statistical model-derived analysis. Gynecol Endocrinol. 2008;24(1):18-23.
161. Shetty A. Disorders of ovulation. In: Templeton AA. ed. Management of Infertility for the MRCOG and Beyond. London: RCOG press; 2001.
162. Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril. 2001;76(3):543-549.
163. Ng EH, Lau EY, Yeung WS, Ho PC. HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial. Hum Reprod. 2001;16(2):319-325.
164. Gordon UD, Harrison RF, Fawzy M, Hennelly B, Gordon AC. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril. 2001;75(2):324-331.
165. Kilani Z, Dakkak A, Ghunaim S, et al. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod. 2003;18(6):1194-1199.
166. Nyboe Andersen A, Devroey P, Arce J-C, for the MERIT Group. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21(12): 3217-3227.
167. Coelingh Bennink HJ, Fauser BC, Out HJ. Recombinant follicle'stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. Fertil Steril. 1998;69(1):19-25.
168. Loumaye E, Martineau I, Piazzi A, et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Hum Reprod. 1996;11 Suppl 195-107; discussion 117-119.